Vazegepant
Based on 1 publication(s) in Google Scholar
Vazegepant (Zavegepant) is an orally active calcitonin gene-related peptide (CGRP) receptor antagonist. Vazegepant can be used in the study of migraine.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.54%
- CAS No.: 1337918-83-8
- Formule: C36H46N8O3
- Masse moléculaire:638.80
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Heterocyclic Compound Library
HY-L138
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Vazegepant
More
Activité biologique
Vazegepant has a high affinity for the CGRP receptor, and its chemical structure makes it suitable for multiple administration routes, including intranasal, subcutaneous, inhaled, or oral[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1337918-83-8
-
Appearance Solid
-
Masse moléculaire 638.80
-
Formule C36H46N8O3
-
Color White to off-white
-
SMILES
O=C(N1CCC(C2=CC3=C(NC2=O)C=CC=C3)CC1)N[C@H](CC4=CC5=C(NN=C5)C(C)=C4)C(N6CCN(C7CCN(C)CC7)CC6)=O
-
Synonyms
Zavegepant; BHV-3500
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvant et solubilité
DMSO : 50 mg/mL (78.27 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureté et documentation
-
Fiche technique (273 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Moreno-Ajona D, et al. Gepants, calcitonin-gene-related peptide receptor antagonists: what could be their role in migraine treatment? Curr Opin Neurol. 2020 Jun;33(3):309-315. [Content Brief]
[2]. Gene M Dubowchik, et al. Blocking the CGRP Pathway for Acute and Preventive Treatment of Migraine: The Evolution of Success. [Content Brief]
[4]. Jéssica Barreto Ribeiro Dos Santos, et al. Small-molecule CGRP receptor antagonists: A new approach to the acute and preventive treatment of migraine. Eur J Pharmacol.2022 May 5:922:174902. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.5654 mL | 7.8272 mL | 15.6544 mL | 39.1359 mL |
| 5 mM | 0.3131 mL | 1.5654 mL | 3.1309 mL | 7.8272 mL | |
| 10 mM | 0.1565 mL | 0.7827 mL | 1.5654 mL | 3.9136 mL | |
| 15 mM | 0.1044 mL | 0.5218 mL | 1.0436 mL | 2.6091 mL | |
| 20 mM | 0.0783 mL | 0.3914 mL | 0.7827 mL | 1.9568 mL | |
| 25 mM | 0.0626 mL | 0.3131 mL | 0.6262 mL | 1.5654 mL | |
| 30 mM | 0.0522 mL | 0.2609 mL | 0.5218 mL | 1.3045 mL | |
| 40 mM | 0.0391 mL | 0.1957 mL | 0.3914 mL | 0.9784 mL | |
| 50 mM | 0.0313 mL | 0.1565 mL | 0.3131 mL | 0.7827 mL | |
| 60 mM | 0.0261 mL | 0.1305 mL | 0.2609 mL | 0.6523 mL |
Vazegepant Related Classifications
HY-134992 Related Classifications
Powered by Bioz